{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T18:27:01Z","timestamp":1795199221634,"version":"4.10.3"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Cystic Fibrosis Foundation","award":["005254GE323"],"award-info":[{"award-number":["005254GE323"]}],"id":[{"id":"https:\/\/ror.org\/00ax59295","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive, monogenic disorder that affects individuals of all races and ethnicities. It was historically viewed as a pediatric disease, but with comprehensive care and therapeutic advances, adults with CF now outnumber children living with CF in the United States, and the median predicted life expectancy is approximately 61 years. Since 2010, a new drug class called CF transmembrane conductance regulator (CFTR) modulators has emerged and led to improved health outcomes for most people with CF in the United States. These new medications have likely contributed to a doubling of pregnancies among women with CF in recent years. In the setting of increased fertility, people with CF should consider contraception when pregnancy is not desired. For people with CF who are seeking pregnancy, preconception consultation with expertise in maternal\u2013fetal medicine and genetics and a dedicated CF team is important because of the increased morbidity among pregnant people with CF. Breastfeeding is possible and encouraged when taking CFTR modulators, although the pediatrician should monitor the infant for possible side effects given established transfer through breast milk. Single-gene noninvasive prenatal testing is emerging and offers a new strategy to screen for fetal CF, which is increasingly important with emerging evidence that transplacental transfer of CFTR modulators may delay, prevent, or reverse multiple CF manifestations for the fetus with CF. Research is ongoing to study pregnancy and parenthood in the modern era in people with CF.<\/jats:p>","DOI":"10.1097\/aog.0000000000006084","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T21:02:34Z","timestamp":1759438954000},"page":"479-490","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Pregnancy in Patients With Cystic Fibrosis"],"prefix":"10.1097","volume":"147","author":[{"given":"Beth L.","family":"Pineles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci M.","family":"Kazmerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Foil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea H.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Szentpetery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1373\/clinchem.2010.159285","article-title":"Cystic fibrosis carrier testing in an ethnically diverse US population","volume":"57","author":"Rohlfs","year":"2011","journal-title":"Clin Chem"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.21037\/tau.2020.04.05","article-title":"Genetics of CFTR and male infertility","volume":"10","author":"Bieniek","year":"2021","journal-title":"Transl Androl Urol"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"Anderson","year":"1938","journal-title":"Am J Dis Child"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/AOG.0000000000001952","article-title":"Carrier screening for genetic conditions. Committee Opinion No. 691. American College of Obstetricians and Gynecologists","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1001\/jama.2021.5086","article-title":"Tackling the misconception that cystic fibrosis is a \u201cWhite people's disease\u201d","volume":"325","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2022.07.010","article-title":"Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening","volume":"22","author":"McColley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.GIM.0000139506.11694.7C","article-title":"Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel","volume":"6","author":"Watson","year":"2004","journal-title":"Genet Med"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijns11020024","article-title":"Cystic fibrosis newborn screening: a systematic review-driven consensus guideline from the United States Cystic Fibrosis Foundation","volume":"11","author":"McGarry","year":"2025","journal-title":"Int J Neonatal Screen"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/j.gim.2023.100867","article-title":"Updated recommendations for CFTR carrier screening: a position statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Deignan","year":"2023","journal-title":"Genet Med"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet Med"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"100334","DOI":"10.1016\/j.gim.2022.10.014","article-title":"Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions","volume":"25","author":"Hoskovec","year":"2023","journal-title":"Genet Med"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"e2240829","DOI":"10.1001\/jamanetworkopen.2022.40829","article-title":"Association of patient and site-of-care characteristics with reproductive carrier screening timing in a large integrated health system","volume":"5","author":"Hull","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcf.2022.08.003","article-title":"Partner perspectives on women's sexual and reproductive healthcare in cystic fibrosis","volume":"22","author":"Ehrenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"R23-20261120","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"R24-20261120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and Cystic Fibrosis Patient Registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R25-20261120","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"R26-20261120","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"R30-20261120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R31-20261120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R33-20261120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-20261120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MCP.0000000000001009","article-title":"The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis","volume":"29","author":"Jain","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"R35-20261120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jcf.2017.01.008","article-title":"Pregnancy among cystic fibrosis women in the era of CFTR modulators","volume":"16","author":"Heltshe","year":"2017","journal-title":"J Cyst Fibros"},{"key":"R37-20261120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2018.10.009","article-title":"Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age","volume":"18","author":"Shteinberg","year":"2019","journal-title":"J Cyst Fibros"},{"key":"R38-20261120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jcf.2023.03.013","article-title":"Cervical mucus quality in females with and without cystic fibrosis","volume":"22","author":"Roe","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R39-20261120","first-page":"100277","article-title":"Gynecologic health care for females with cystic fibrosis","volume":"26","author":"Roe","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"R40-20261120","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcf.2023.03.020","article-title":"Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis","volume":"22","author":"Peng","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R41-20261120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2015.07.007","article-title":"Contraception in women with cystic fibrosis: a systematic review of the literature","volume":"93","author":"Roe","year":"2016","journal-title":"Contraception"},{"key":"R43-20261120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jcf.2025.02.004","article-title":"The impact of pregnancy on mortality and lung function in cystic fibrosis patients","volume":"24","author":"Mohabir","year":"2025","journal-title":"J Cyst Fibros"},{"key":"R44-20261120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201211-108OC","article-title":"Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis","volume":"10","author":"Schechter","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"R45-20261120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2013.08.004","article-title":"Cystic fibrosis and pregnancy in the modern era: a case control study","volume":"13","author":"Ahluwalia","year":"2014","journal-title":"J Cyst Fibros"},{"key":"R46-20261120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/GRF.0b013e3181deb448","article-title":"Cystic fibrosis in pregnancy","volume":"53","author":"Whitty","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"R47-20261120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1378\/chest.118.1.85","article-title":"Pregnancy in cystic fibrosis: fetal and maternal outcome","volume":"118","author":"Gilljam","year":"2000","journal-title":"Chest"},{"key":"R48-20261120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R49-20261120","doi-asserted-by":"crossref","first-page":"116155","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators elexacaftor\/tezacaftor\/ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R50-20261120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2021.06.005","article-title":"Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung","volume":"20","author":"Qiu","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R51-20261120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"R52-20261120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R53-20261120","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R54-20261120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators\u2014an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"R55-20261120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R56-20261120","doi-asserted-by":"crossref","first-page":"220005","DOI":"10.1183\/20734735.0005-2022","article-title":"Management of pregnancy in cystic fibrosis","volume":"18","author":"Montemayor","year":"2022","journal-title":"Breathe (Sheff)"},{"key":"R57-20261120","doi-asserted-by":"crossref","first-page":"1901208","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ task force statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"key":"R58-20261120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/AOG.0000000000004959","article-title":"Trends in and outcomes of deliveries complicated by cystic fibrosis","volume":"140","author":"Schmidt","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R59-20261120","doi-asserted-by":"crossref","first-page":"102809","DOI":"10.1016\/j.jogc.2025.102809","article-title":"Characteristics, clinical outcomes and healthcare utilization of women with cystic fibrosis and their live newborns delivered in the hospital setting","volume":"47","author":"Cheng","year":"2025","journal-title":"J Obstet Gynaecol Can"},{"key":"R60-20261120","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.ajog.2014.07.018","article-title":"Medical and obstetric complications among pregnant women with cystic fibrosis","volume":"212","author":"Patel","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R61-20261120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/14767058.2016.1161747","article-title":"Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis","volume":"30","author":"Jelin","year":"2017","journal-title":"J Maternal Fetal Neonatal Med"},{"key":"R62-20261120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","article-title":"CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study","volume":"24","author":"Chouchana","year":"2025","journal-title":"J Cyst Fibros"},{"key":"R63-20261120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest"},{"key":"R64-20261120","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"R65-20261120","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/1471-0528.12040","article-title":"The outcome of pregnancies in women with cystic fibrosis\u2014single centre experience 1998-2011","volume":"120","author":"Thorpe-Beeston","year":"2013","journal-title":"BJOG"},{"key":"R66-20261120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/aogs.13185","article-title":"Pregnancy outcome in women with cystic fibrosis-related diabetes","volume":"96","author":"Reynaud","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R67-20261120","doi-asserted-by":"crossref","first-page":"6388254","DOI":"10.1155\/cria\/6388254","article-title":"Anesthetic management and considerations for cesarean delivery in a patient with cystic fibrosis","volume":"2025","author":"Pham","year":"2025","journal-title":"Case Rep Anesthesiol"},{"key":"R68-20261120","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R69-20261120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"key":"R70-20261120","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/nu13093263","article-title":"Breastfeeding in cystic fibrosis: a systematic review on prevalence and potential benefits","volume":"13","author":"Colombo","year":"2021","journal-title":"Nutrients"},{"key":"R71-20261120","doi-asserted-by":"crossref","first-page":"1274303","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R72-20261120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation: results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R73-20261120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinthera.2023.01.016","article-title":"The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis","volume":"45","author":"Taylor-Cousar","year":"2023","journal-title":"Clin Ther"},{"key":"R74-20261120","doi-asserted-by":"crossref","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"R75-20261120","doi-asserted-by":"crossref","first-page":"e002383","DOI":"10.1136\/bmjresp-2024-002383","article-title":"Assessing the health impacts of parenthood on people with cystic fibrosis: the HOPeCF prospective cohort protocol","volume":"11","author":"Kazmerski","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"R76-20261120","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"R77-20261120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R78-20261120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"key":"R79-20261120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"key":"R81-20261120","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.3390\/jcm9092706","article-title":"CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J Clin Med"},{"key":"R82-20261120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","article-title":"A therapy for most with cystic fibrosis","volume":"180","author":"Bear","year":"2020","journal-title":"Cell"},{"key":"R83-20261120","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.11.014","article-title":"Atomic structure of the cystic fibrosis transmembrane conductance regulator","volume":"167","author":"Zhang","year":"2016","journal-title":"Cell"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:01:16Z","timestamp":1795179676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006084","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"2025-04-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}